Perez R, Padavic K, Krigel R, Weiner L
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Cancer. 1991 May 15;67(10):2512-7. doi: 10.1002/1097-0142(19910515)67:10<2512::aid-cncr2820671021>3.0.co;2-5.
The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin-2 (IL-2) and gamma-interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL-2 (3.75 x 10(6) cetus units/m2 intravenous bolus three times per week) and gamma-IFN (0.1 mg/m2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma-IFN and IL-2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.